Top news story of the day:
Seagen and Zai Lab announced regional strategic collaboration and licensing agreement for TIVDAK
Zai Lab announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in Greater China.
Seagen will receive an upfront payment of $30 million, along with development, regulatory, and commercial milestone payments, as well as tiered royalties on net sales of TIVDAK in the Zai Lab territory.
TIVDAK is the first and only ADC approved in the U.S. for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression during or after chemotherapy.
A confirmatory Phase III open-label, randomized, global clinical trial named “innovaTV 301” is currently ongoing. It is intended to verify and describe clinical benefits in the U.S. and support further global regulatory applications.
TIVDAK is being co-developed and co-commercialized by Genmab and Seagen under an agreement in which the companies, regarding certain major markets, including China, share costs and profits for the product on a 50/50 basis, including upfront payments, future milestones and royalties received under the collaboration and licensing agreement with Zai Lab.
In other news:
Jiuzhou Pharma acquired a 100% interest in Sandoz (China)'s Zhongshan Pharmaceutical Plant to serve as Jiuzhou's CDMO pharmaceutical production base.
A 5.5-year follow-up of a Phase III trial of Cecolin, a China-made bivalent HPV vaccine, was published in The Lancet Infectious Diseases journal. Data show that Ceolin has a 100% protection rate against the endpoint of HPV16/18-related precancerous lesions in women aged 18 to 45 years and can induce high levels of antibodies with good immune persistence and safety.
Joincare Pharmaceutical has successfully issued Global Depositary Receipts (GDR) and is officially listed on the SWX Swiss Exchange.
By Sarina Yang